Results 151 to 160 of about 3,496 (176)

VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance

Blood Coagulation & Fibrinolysis, 2016
Warfarin is the most commonly prescribed anticoagulant drug; however, a narrow therapeutic range and a high risk of bleeding or stroke complicate its clinical use. Warfarin resistance was defined as prolonged warfarin requirements of more than 15 mg/day to achieve therapeutic anticoagulation or failure to achieve therapeutic anticoagulation with more ...
Hanan, Azzam, Hossam, Elwakeel, Ibrahim, Awad, Reham, El-Farahaty, Abdel-Hady, El-Gilany, Solafa, El-Sharawy   +5 more
openaire   +2 more sources

VKORC1 C1173TandVKORC1 G-1639AGene Polymorphisms in Turkish Behçet’s Patients with Ocular and Non-ocular Involvement

Ophthalmic Genetics, 2013
Behçet's disease (BD) is a multisystemic vasculitis with unknown etiology. Vitamin K epoxide reductase complex subunit 1 (VKORC1) is the key enzyme in the formation of active vitamin K that is a cofactor of various coagulation factors. Polymorphisms of the VKORC1 may affect the levels of active forms of vitamin K-dependent coagulation proteins and the ...
Helin Deniz, Demir, Hüseyin, Ortak, Şemsettin, Şahin, Ömer, Ateş, Ismail, Benli, Ahmet, İnanır   +5 more
openaire   +2 more sources

Platform Evaluation for Rapid Genotyping of CYP2C9 and VKORC1 Alleles

Personalized Medicine, 2009
Warfarin is a commonly prescribed drug with a narrow therapeutic index. Adverse drug reactions owing to over- or under-dosing are common. It is now established that genetic differences between individuals play a major role in warfarin metabolism. In particular, common variants in CYP2C9 (*2 and *3) and VKORC1 (-1639G>A) have been associated with a ...
Victoria A, Joshi, Elizabeth, Duffy, Birgit H, Funke, Lisa M, Farwell, Debora, Mancini-Dinardo, Raju, Kucherlapati   +5 more
openaire   +2 more sources

A pharmacophore hypothesis and computationally optimized lead compounds for VKORC1

2017 IEEE 7th International Conference on Computational Advances in Bio and Medical Sciences (ICCABS), 2017
Warfarin is a popular pharmaceutical anticoagulant that targets the vitamin K epoxide reductase complex sub-unit 1, encoded by the gene VKORC1, but warfarin can be dangerous since it can cause bleeding. A first step in finding better anticoagulants that target the same enzyme is structure based lead molecule optimization using computational tools. This
openaire   +2 more sources

Gydymo varfarinu individualizavimas: VKORC1 (-1639G

2009
Aktualumas. Varfarinas yra vienas plačiausiai Lietuvoje ir pasaulyje vartojamų netiesioginio veikimo antigoaguliantų, psižymintis dideliu terapinės dozės svyravimu tarp atskirų ligonių. Nustatyta, kad individuali varfarino dozė priklauso nuo vitamino K epoksido reduktazės komplekso 1 (VKORC1) aktyvumo ir vaisto metabolizmo greičio. [...].
Tatarūnas, Vacis, Lesauskaitė, Vaiva, Veikutienė, Audronė, Jakuška, Povilas, Benetis, Rimantas   +4 more
openaire   +1 more source

Population variation in VKORC1 haplotype structure

Journal of Thrombosis and Haemostasis, 2006
S, Marsh, C R, King, R M, Porche-Sorbet, T J, Scott-Horton, C S, Eby   +4 more
openaire   +2 more sources

Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups

Blood, 2010
Guilherme Suarez-Kurtz, Hersh Sagreiya, Mia Wadelius   +2 more
exaly  

Combined CYP2C9 , VKORC1 and CYP4F2 Frequencies among Racial and Ethnic Groups

Pharmacogenomics, 2010
Robert Desnick, Stuart Scott, Inga Peter   +2 more
exaly  

Main haplotypes and mutational analysis of vitamin K epoxide reductase (VKORC1) in a Swedish population: a retrospective analysis of case records

Journal of Thrombosis and Haemostasis, 2006
Abdimajid Osman
exaly  

VKORC1 mutations detected in patients resistant to vitamin K antagonists are not all associated with a resistant VKOR activity

Journal of Thrombosis and Haemostasis, 2012
Isabelle Fourel
exaly